Loading cancer entity…
Loading cancer entity…
Clinical trials
10,628 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,642)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00003337 | Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma | unknown | Phase 3 | 100 | Gilead SciencesINDUSTRY | 5 | Aug 16, 2021 | clinicaltrials |
| NCT00003338 | Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma | unknown | Phase 2 / Phase 3 | 60 | Gilead SciencesINDUSTRY | 5 | Aug 16, 2021 | clinicaltrials |
| NCT05006469 |
| Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma |
| unknown |
| Phase 3 |
| 10 |
| Liao AijunOTHER |
| 1 |
| Aug 16, 2021 |
| clinicaltrials |
| NCT00003816 | Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer | completed | Phase 2 / Phase 3 | 361 | Roswell Park Cancer InstituteOTHER | 1 | Aug 13, 2021 | clinicaltrials |
| NCT00369564 | Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer | completed | Phase 3 | 250 | University of South FloridaOTHER | 1 | Aug 11, 2021 | clinicaltrials |
| NCT04910594 | Clinical Study the Efficacy and Safety of Rh-EPO in the Treatment of Anemia in Lymphoma | unknown | Phase 3 | 130 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 11, 2021 | clinicaltrials |
| NCT01122472 | Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP(REMARC) | completed | Phase 3 | 650 | The Lymphoma Academic Research OrganisationOTHER | 9 | Jul 26, 2021 | clinicaltrials |
| NCT02579863 | Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185) | terminated | Phase 3 | 310 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 20, 2021 | clinicaltrials |
| NCT04288765 | Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma | withdrawn | Phase 3 | 0 | Grupo Cooperativo de Hemopatías MalignasOTHER | 1 | Jul 9, 2021 | clinicaltrials |
| NCT03720041 | Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma(FiTNEss) | unknown | Phase 3 | 740 | University of LeedsOTHER | 1 | Jun 15, 2021 | clinicaltrials |
| NCT00967343 | Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor | terminated | Phase 2 / Phase 3 | 40 | Kiadis PharmaINDUSTRY | 7 | Jun 14, 2021 | clinicaltrials |
| NCT00052936 | Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma | completed | Phase 3 | 1,506 | German High-Grade Non-Hodgkin's Lymphoma Study GroupOTHER | 2 | May 18, 2021 | clinicaltrials |
| NCT00053768 | Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma | completed | Phase 3 | 392 | German High-Grade Non-Hodgkin's Lymphoma Study GroupOTHER | 2 | May 18, 2021 | clinicaltrials |
| NCT01100502 | A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial) | completed | Phase 3 | 329 | Seagen Inc.INDUSTRY | 13 | May 14, 2021 | clinicaltrials |
| NCT01419665 | GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)(ASSIST_FL) | completed | Phase 3 | 629 | SandozINDUSTRY | 26 | May 14, 2021 | clinicaltrials |
| NCT04880746 | Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study | unknown | Phase 3 | 266 | Ruijin HospitalOTHER | 1 | May 11, 2021 | clinicaltrials |
| NCT00317096 | FCM Versus R-FCM Followed by R-Maintenance or Observation Only | unknown | Phase 3 | 319 | Ludwig-Maximilians - University of MunichOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT00003056 | Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation | terminated | Phase 3 | 105 | Baxalta now part of ShireINDUSTRY | 2 | May 6, 2021 | clinicaltrials |
| NCT00773747 | Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN) | completed | Phase 3 | 637 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 30, 2021 | clinicaltrials |
| NCT02112175 | Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM(ARUMM) | completed | Phase 3 | 46 | CelgeneINDUSTRY | 5 | Apr 14, 2021 | clinicaltrials |
| NCT02128061 | Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+ | completed | Phase 3 | 250 | The Lymphoma Academic Research OrganisationOTHER | 2 | Apr 13, 2021 | clinicaltrials |
| NCT02260804 | To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma | completed | Phase 3 | 258 | CelltrionINDUSTRY | 1 | Apr 8, 2021 | clinicaltrials |
| NCT00302003 | Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma | completed | Phase 3 | 287 | Children's Oncology GroupNETWORK | 1 | Mar 30, 2021 | clinicaltrials |
| NCT03800095 | Early Palliative Care for Patients With Haematological Malignancies(CALVI) | unknown | Phase 3 | 140 | University Hospital, Clermont-FerrandOTHER | 1 | Mar 24, 2021 | clinicaltrials |
| NCT04799314 | PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT | unknown | Phase 3 | 132 | Ruijin HospitalOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT02085655 | PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma | unknown | Phase 3 | 264 | Huiqiang HuangOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT00278421 | Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma | completed | Phase 3 | 592 | German High-Grade Non-Hodgkin's Lymphoma Study GroupOTHER | 3 | Mar 11, 2021 | clinicaltrials |
| NCT03440411 | Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment(PO-3887) | terminated | Phase 3 | 9 | Fondazione EMN Italy OnlusOTHER | 1 | Mar 10, 2021 | clinicaltrials |
| NCT02165397 | Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia | completed | Phase 3 | 181 | Pharmacyclics LLC.INDUSTRY | 9 | Mar 3, 2021 | clinicaltrials |
| NCT00003650 | Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma | completed | Phase 3 | 179 | UNICANCEROTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT00004179 | Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma | completed | Phase 3 | 475 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 18 | Feb 15, 2021 | clinicaltrials |
| NCT01652261 | Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11)(H11) | withdrawn | Phase 3 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Feb 15, 2021 | clinicaltrials |
| NCT04342936 | Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma | unknown | Phase 3 | 56 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 8, 2021 | clinicaltrials |
| NCT00433433 | Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma(H10) | unknown | Phase 3 | 1,952 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Feb 3, 2021 | clinicaltrials |
| NCT00004031 | SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma | completed | Phase 3 | 397 | SWOG Cancer Research NetworkNETWORK | 2 | Feb 2, 2021 | clinicaltrials |
| NCT02910063 | Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL | completed | Phase 2 / Phase 3 | 41 | AmgenINDUSTRY | 8 | Jan 13, 2021 | clinicaltrials |
| NCT01578499 | A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)(ALCANZA) | completed | Phase 3 | 131 | Millennium Pharmaceuticals, Inc.INDUSTRY | 12 | Jan 5, 2021 | clinicaltrials |
| NCT00452439 | A Study of Actonel for the Prevention of Bone Loss | completed | Phase 3 | 72 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 28, 2020 | clinicaltrials |
| NCT02951156 | Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)(Javelin DLBCL) | terminated | Phase 3 | 29 | PfizerINDUSTRY | 8 | Dec 17, 2020 | clinicaltrials |
| NCT00577993 | Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients | completed | Phase 3 | 210 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 16, 2020 | clinicaltrials |
| NCT00515554 | HD18 for Advanced Stages in Hodgkins Lymphoma | completed | Phase 3 | 1,500 | University of CologneOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT01102426 | Aplidin - Dexamethasone in Relapsed/Refractory Myeloma(ADMYRE) | completed | Phase 3 | 255 | PharmaMarINDUSTRY | 19 | Nov 10, 2020 | clinicaltrials |
| NCT00736320 | HD16 for Early Stage Hodgkin Lymphoma(HD16) | unknown | Phase 3 | 1,150 | University of CologneOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT00551239 | Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma | withdrawn | Phase 3 | 0 | CTI BioPharmaINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02809053 | A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma(RAMO-2) | completed | Phase 3 | 315 | Archigen Biotech LimitedINDUSTRY | 14 | Oct 8, 2020 | clinicaltrials |
| NCT00577161 | Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL | withdrawn | Phase 3 | 0 | CTI BioPharmaINDUSTRY | 1 | Oct 5, 2020 | clinicaltrials |
| NCT02657785 | Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy | recruiting | Phase 2 / Phase 3 | 100 | Navy General Hospital, BeijingOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT02836158 | Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL | recruiting | Phase 2 / Phase 3 | 100 | Navy General Hospital, BeijingOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT03242902 | To Decrease Fatigue With Light Therapy(SPARKLE) | completed | Phase 3 | 166 | The Netherlands Cancer InstituteOTHER | 1 | Sep 1, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Aug 16, 2021source: clinicaltrials